Literature DB >> 10567879

Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protein levels.

D Luo1, S C Cheng, H Xie, Y Xie.   

Abstract

Bcl-2 protein is one of the major apoptosis regulators. The study examines the effect of Bcl-2 protein on the chemosensitivity of a human hepatocellular carcinoma cell line, QGY-7703. Western blot analysis showed that Bcl-2 and Bax proteins were expressed in QGY-7703 cells. Characteristic features of Taxol- and doxorubicin-induced apoptosis were evidenced by the Annexin-V binding assay, TUNEL and DAPI staining. At constant Bax protein levels, stable sense and antisense gene-transfected QGY-7703 cells showed that constitutive expression of Bcl-2 could render the cells more resistant to Taxol and doxorubicin. Contrarily, decreased Bcl-2 levels caused the cells to be more sensitive to the drugs. As Bcl-2 levels are directly proportional to the resistance of QGY-7703 cells to Taxol and doxorubicin, manipulation of Bcl-2 could be performed to enhance the sensitivity of liver cancer to chemotherapeutic agents. Copyright 1999 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567879     DOI: 10.1159/000030097

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  7 in total

1.  A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798).

Authors:  J J Knox; X E Chen; R Feld; M Nematollahi; R Cheiken; G Pond; J A Zwiebel; S Gill; M Moore
Journal:  Invest New Drugs       Date:  2007-12-04       Impact factor: 3.850

2.  Antisense-induced down-regulation of thymidylate synthase and enhanced cytotoxicity of 5-FUdR in 5-FUdR-resistant HeLa cells.

Authors:  P J Ferguson; J M DeMoor; M D Vincent; J Koropatnick
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

3.  Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid inhibits hepatocellular carcinoma in vitro and in vivo via stabilizing IkBα.

Authors:  George G Chen; Jackie Leung; Nian Ci Liang; Li Li; Kefeng Wu; Ursula P F Chan; Billy C S Leung; Mingyue Li; Jing Du; Yi Feng Deng; Xianling Gong; Yingnian Lv; Ernest C W Chak; Paul B S Lai
Journal:  Invest New Drugs       Date:  2012-01-07       Impact factor: 3.850

4.  Molecular mechanisms of chemoresistance in osteosarcoma (Review).

Authors:  Hongtao He; Jiangdong Ni; Jun Huang
Journal:  Oncol Lett       Date:  2014-03-04       Impact factor: 2.967

5.  Combined Modality Therapy Based on Hybrid Gold Nanostars Coated with Temperature Sensitive Liposomes to Overcome Paclitaxel-Resistance in Hepatic Carcinoma.

Authors:  Hongyan Zhu; Weili Han; Ye Gan; Qiaofeng Li; Xiaolan Li; Lanlan Shao; Dan Zhu; Hongwei Guo
Journal:  Pharmaceutics       Date:  2019-12-15       Impact factor: 6.321

6.  Targeted expression of BikDD combined with metronomic doxorubicin induces synergistic antitumor effect through Bax activation in hepatocellular carcinoma.

Authors:  Huei-Yue Dai; Hui-Yu Chen; Wei-Chen Lai; Mien-Chie Hung; Long-Yuan Li
Journal:  Oncotarget       Date:  2015-09-15

7.  Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models.

Authors:  Zhihua Ren; Yanan Wang; Wenhong Jiang; Wei Dai; Yongping Jiang
Journal:  PLoS One       Date:  2014-09-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.